• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Lipodystrophy - Pipeline Review, Q4 2010 - Product Image

Lipodystrophy - Pipeline Review, Q4 2010

  • Published: December 2010
  • 33 pages
  • Global Markets Direct

Lipodystrophy - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Lipodystrophy Pipeline Review, Q4 2010”, provides an overview of the Lipodystrophy therapeutic pipeline. This report provides information on the therapeutic development for Lipodystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lipodystrophy. “Lipodystrophy-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Lipodystrophy.
- A review of the Lipodystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lipodystrophy Overview
Therapeutics Development
An Overview of Pipeline Products for Lipodystrophy
Lipodystrophy Therapeutics under Development by Companies
Lipodystrophy Therapeutics under Investigation by Universities/Institutes
Companies Involved in Lipodystrophy Therapeutics Development
Universities/Institutes Involved in Lipodystrophy Therapeutics Development
Lipodystrophy Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
Fenofibrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pravastatin Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pravastatin Sodium + Fenofibrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lipodystrophy - Featured News
Nov 11, 2010: Theratechnologies Receives FDA Approval For EGRIFTA For Reduction Of Excess Abdominal Fat In HIV-Infected Patients With Lipodystrophy
Sep 13, 2010: Theratechnologies Tesamorelin Data Presented At The Interscience Conference On Antimicrobial Agents And Chemotherapy 50th Annual Meeting
Jul 20, 2010: Update On Timeline For FDA Action Date For Theratechnologies’ Tesamorelin New Drug Application
Jul 20, 2010: Theratechnologies Receives Update On Timeline For FDA Action Date For Tesamorelin NDA
Jun 24, 2010: Theratechnologies Announces Publication Of Combined Tesamorelin Phase III Results In JCEM
May 27, 2010: Theratechnologies Announces Positive Vote By FDA Advisory Committee For Tesamorelin
Mar 22, 2010: FDA Confirms Date For Advisory Committee Review Of Theratechnologies' Tesamorelin NDA
Feb 25, 2010: Theratechnologies Announces Tentative New Date For FDA Advisory Committee Review Of Tesamorelin NDA
Feb 24, 2010: Theratechnologies Announces FDA Advisory Committee Review Meeting On NDA Application Of Tesamorelin
Jan 18, 2010: Theratechnologies Reports Date For FDA Advisory Committee Review Of The Tesamorelin New Drug Application
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos